Duchenne families face another heartbreak with halt to gene therapy

A muscular dystrophy disease is devastating on its own, but a Sarepta treatment had offered hope.

July 24, 2025 Check out STAT+

Sponsored By

Photo courtesy of Jennifer Hill Blair STAT+ | For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak A muscular dystrophy disease is devastating on its own, but Sarepta Therapeutics' Elevydis, currently shelved, had offered hope. By Jason Mast Safety of fluoride supplements, and freedom of choice, debated at FDA meeting As RFK Jr. defends fluoride bans as medical freedom, the FDA weighs removing fluoride supplements — an alternative for cavity protection By Anil Oza STAT+ | As ambient scribes face off, Doximity lures doctors with a free option Can a free AI scribe change who can use this tech? Doximity bets on easy access and growing demand from providers who can't afford high-end systems. By Katie Palmer Alex Hogan/STAT Doctors are biased against higher-weight patients. Can nutrition education help them change? RFK Jr. wants med schools to teach nutrition. Experts call it a chance to teach doctors how to talk about food and weight loss without shaming patients. By Sarah Todd STAT+ | UnitedHealth confirms DOJ investigations into Medicare practices, says it's cooperating UnitedHealth said it is cooperating with DOJ criminal and civil investigations into its Medicare business practices. By Tara Bannow STAT+ | Why Sarepta may not survive its current gene therapy crisis  In this edition of "Adam's Biotech Scorecard," Adam also looks at the situation facing Sarepta's CEO, whose job is now on the line because of Elevydis. By Adam Feuerstein ADOBE Opinion: How states can mitigate Trump's Medicaid cuts – and set their health care systems on a better path States can minimize federal Medicaid cuts and even set their health care systems on a better long-term trajectory. By Hayden Rooke-Ley Opinion: The U.S. must reconsider its decision to reject amendments to a global health treaty Undermining the International Health Regulation amendments puts U.S. health at risk, writes former Biden official Stephanie Psaki. By Stephanie Psaki

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser